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doi:10.1016/j.ejvs.2010.12.017Abstract Objective: Recent interest has focussed on the role of biomarkers to predict
outcome in patients undergoing major vascular surgery. We wished to determine if pre- and
postoperative N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) levels could predict all-
cause mortality (ACM; primary aim) and major adverse cardiac event (MACE) (secondary aim)
in the medium-term follow-up in patients who have undergone elective major vascular surgery.
Method: Patients who underwent major elective vascular surgery (nZ 136) were followed up
for up to 2 years. ACM and first MACE episodewere identified from the case notes and the patient
management system database of the hospital intranet.
Results: One patient was lost to follow-up. In the mean follow-up of 654 days, 27 (20%) died and
23 (17%) patients suffered a MACE. Receiver operator curve (ROC) analysis showed that a pre-
operative NT-pro-BNP level with a cut-off of 359 pg ml1 had a sensitivity and specificity of
73% each (area under the curve (AUC) 80%, p < 0.001) in predicting ACM and sensitivity of 74%
and specificity of 71% (AUC 75%, p < 0.001) to detect a MACE. The overall 2-year survival rate
was 84%, 93% in the<359 pgml1 group and 68% in the359 pgml1 group (p< 0.001). Following
multivariate analysis, pre-operative NT-pro-BNP at a value of 359 pg ml1 remained an inde-
pendent predictor of ACM (odds ratio 3.6 (confidence interval (CI): 1.6e8.1), pZ 0.002) Post-
operative NT-pro-BNP was a predictor of mortality but not a MACE.
Conclusion: This study has shown that pre-operative NT-pro-BNP is an independent predictor of
ACM and MACE on medium-term follow-up.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.24 559446; fax: þ44 1224 552553.
rs.org.uk (S. Rajagopalan).
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658 S. Rajagopalan et al.Major vascular surgery is associated with a high morbidity
and mortality especially from cardiovascular events.1e3
There is an increasing emphasis on risk stratification and
patient optimisation, particularly for elective procedures
such as aortic aneurysm repair.4 The recognised low
predictive value of non-invasive testing of cardiac function,
coupled with limited resources, highlights the need for
alternative methods of predicting cardiac risk.5 Recent
interest has focused on the potential role of biomarkers for
cardiac risk assessment in patients who undergo elective
vascular surgery. In particular, B-type natriuretic peptide
(BNP) and N-terminal pro-B-type natriuretic peptide (NT-
pro-BNP) have been shown to be more accurate predictors
of major adverse cardiac events (MACEs) than the Revised
Cardiac Risk Index.6,7
A recent meta-analysis of seven studies has shown that
NT-pro-BNP is a powerful, independent predictor of
cardiovascular events in the 30-day follow-up after surgery
with an odds ratio of 19.3 (confidence interval (CI):
8.7e43.7).8 With the advent of a point-of-care tool for
natriuretic peptide assays, there is the potential in the
future to identify at-risk patients in order for targeted
cardiac optimisation in the pre- and postoperative periods.
We have previously shown in a cohort of 136 patients
undergoing elective open repair of aortic aneurysm or
lower limb revascularisation for severe limb ischaemia that
preoperative NT-pro-BNP was an independent predictor of
30-day postoperative myocardial injury as assessed by a rise
in troponin-I. The aim of this study was to determine if NT-
pro-BNP could predict ACM in the medium-term follow-up in
patients undergoing major vascular surgery. The secondary
aim was to determine if it could predict MACE.Methods
Consecutive patients who underwent major elective
vascular surgery (nZ 136), which includes open abdominal
aortic aneurysm (AAA) repair and aorto-femoral and infra-
inguinal revascularisation for critical limb ischaemia, were
recruited on admission for the above procedures over a 20-
month period (August 2004eMarch 2006). Eighteen patients
did not fulfil the criteria and were excluded, a further five
patients agreed to participate in the study but did not
proceed to surgery and one patient withdrew. Co-morbid-
ities such as ischaemic heart disease (defined as history of
myocardial infarction (MI) or a positive exercise test,
current complaint of chest pain considered to be secondary
to myocardial ischaemia, use of nitrate therapy or elec-
trogram (ECG) with pathological Q waves), diabetes melli-
tus, hypertension and baseline serum creatinine values
were recorded. Patients were retrospectively followed up
for 2 years.7 Information on the MACE and all-cause
mortality (ACM) was obtained from the case notes and the
hospital intranet’s patient database. MACE was defined as
MI (defined by American College of Cardiology/American
Heart Association task force),9 death due to an obvious
cardiac cause or coronary revascularisation. The time point
of first MACE and time of death were collected. Patients
were censored if they died or after the first MACE event.
Ethical approval was obtained from the Grampian
Regional Ethical Committee and written informed consentwas obtained from each patient. Patients with acute limb
ischaemia, current infections or symptomatic or ruptured
AAA were excluded. Full details of the inclusion and
exclusion criteria were published previously.7,10 All patients
were on statin for at least 6e8 weeks before surgery and
75 mg aspirin therapy, which was continued in the peri-
operative and postoperative period.
Assays
NT-pro-BNP levels were measured on the plasma sample
taken the day before surgery and on the first postoperative
day after surgery. Blood samples that were collected were
promptly centrifuged and plasma stored in aliquots at 80.
N-terminal pro-B-type natriuretic peptide: The Roche
Elecsys N-terminal pro-B-type natriuretic peptide electro-
chemiluminescence sandwich immunoassay (ECLIA) was
performed on a Roche Elecsys 2010 automated immunoassay
analyser platform (Roche Diagnostics, Basel, Switzerland).
The assay has an analytical sensitivity (lower detection
limit) of 5 pg ml1 and an effective measuring range of
5e35,000 pg ml1. The within run coefficient of variation
(CV) was 2.7% at a concentration of 175 pg ml1, and 1.9% at
1068 pg ml1. Total analytical precision demonstrated a CV
of 3.2% and 2.6% at concentrations of 175 and 1068 pg ml1,
respectively.7
Statistical Analysis
Data are presented as medians with inter-quartile ranges
(IQRs), and significance is developed at the 5% probability
level. Differences between two independent categorical
values were tested with c2 test, and differences between
two continuous independent values were tested with the
ManneWhitney U test. A receiver operating characteristic
(ROC) curve was plotted to assess the ability of pre- and
postoperative NT-pro-BNP to predict MACE and ACM, and
the area under the curve (AUC), with 95% CIs, was calcu-
lated. KaplaneMeier technique and Cox regression analysis
were used for survival analysis. Analysis was done with SPSS
16 software (SPSS Inc, Chicago, IL, USA).
Results
One hundred and thirty-six patients who underwent elec-
tive vascular surgery for critical limb ischemia (CLI) or
infra-renal AAA were followed up. The patient character-
istics are shown in Table 1. One patient died within the
initial 30-day postoperative period from a cerebro-vascular
accident.
All patients were followed up for 2 years, except one
patient who had an AAA repair was lost to follow-up. During
the mean follow-up of 654 days (range 725 days), 27 (20%)
patients died and 23 (17%) suffered a MACE. The cause of
death was cardiac, nZ 16; cerebro-vascular, nZ 2; cancer
n Z 6; Clostridium difficile sepsis, n Z 1; and end-stage
respiratory failure, n Z 2. Patients who had died in the
follow-up period were older and had a higher incidence of
known ischaemic heart disease than those who did not
(p < 0.05) (Table 1).
Figure 1 Receiver operating characteristic curves of pre-
operative plasma NT-pro-BNP against 2 years MACE. AUCZ 75%,
Cut-off: 359 pg ml1; Sensitivity 74% and Specificity 71%.
N-terminal pro-B-type Natriuretic Peptide 659Preoperative NT-pro-BNP
The median preoperative NT-pro-BNP was 277 pg ml1 (IQR
117e561). Patients who died in the follow-up period had
a significantly higher preoperative NT-pro-BNP level than
those who did not (median 686 pg ml1 (IQR 274e1300) vs.
median 234 pg ml1 (IQR 110e398), respectively, p< 0.001).
An optimal discriminatory threshold for preoperative NT-
pro-BNP was 359 pg ml1 for the prediction of both ACM and
MACE. For ACM, the sensitivity and specificity was 73%
each, and for MACE the cut-off value of 359 pg ml1 had
a sensitivity 74% and specificity 71% (Figs. 1 and 2).
At 2 years, the freedom from MACE in patients with
a preoperative NT-pro-BNP level of <359 pg ml1 versus
a level of 359 pg ml1 was 86% versus 54%, p < 0.001
(Fig. 3). The 2-year survival rate was 90% versus 56%,
p < 0.001 for patients with a preoperative NT-pro-BNP level
of <359 pg ml1 compared to a level of 359 pg ml1
(Fig. 4).
Following adjustment for patient risk factors (significant
on univariate analysis e age, ischaemic heart disease and
postoperative troponin rise; Table 1) by the use of a Cox
regression analysis, preoperative NT-pro-BNP at a value
of 359 pg ml1 remained an independent predictor of ACM
(odds ratio 3.6 (CI: 1.6e8.1) p Z 0.002) and MACE (odds
ratio 4.9 (CI: 1.9e12) p Z 0.001).
Postoperative NT-pro-BNP
The median postoperative NT pro-BNP was 431 (187e809)
pg ml1. The value was higher in patients who died in the
follow-up period in comparison to those who survived
738 pg ml1 (462e3328) versus 328 pg ml1 (155e647). ROC
analysis established 625 pg ml1 as an optimal cut-off forTable 1 Patient characteristics in the study cohort.
All-cause
(n Z 109
Male sex 74
Age in years {Median (IQR)} 69 (62e7
Ischaemic heart diseasea 31
Hypertensionb 67
Diabetes mellitus 24
Current smoking 29
Pre-operative NT-pro-BNP pg ml1 {Median (IQR)} 234 (110
Pre-operative NT-pro-BNP  359 pg.ml1 31
Post-operative NT-pro-BNP pg ml1 328 (155
Troponin-I positives 16
Revised Cardiac Risk index (RCRI) class
I 37
II 47
III 20
IV 5
Procedure
AAA repair 24
Lower limb revascularisation 85
Serum creatinine (mmol/l) 94 (80e1
a Angina, myocardial infarction, previous revascularisation.
b Hypertension was defined as a systolic blood pressure greater thapostoperative NT-pro-BNP for the prediction of all-cause
mortality with a sensitivity of 73% and specificity of 75%. This
was also found to be higher in patients, who had a MACE in
comparison to those who did not, (656 pg ml1 (311e3234)
versus 417 pg ml1 (166e695), respectively) p Z 0.01.
However, an optimal cut-off was not feasible using the ROC.
At 2 years, the survival rate was 92% for patients with
a postoperative NT-pro-BNP level of <329 pg ml1 com-
pared to 60% for those with a level of 359 pg ml1,
p < 0.001.
Following adjustment for patient risk factors by the use
of a Cox regression analysis, postoperative NT-pro-BNP atmortality eve
)
All-cause mortality þ ve
(n Z 27)
p-value
18 0.9
5) 76 (75e81) 0.02
16 0.003
19 0.39
9 0.22
9 0.6
e398) 686 (274e1300) <0.001
19 <0.001
e647) 738 (462e3328) <0.001
12 0.001
5 0.203
14
8
0
0 0.007
27
08) 98 (80e118) 0.4
n 140 mm Hg and/or diastolic greater than 90 mm Hg.
Figure 2 Receiver operating characteristic curves of pre-
operative NT-pro-BNP against all-cause mortality: AUC Z 80%,
Cut-offZ 359 pg ml1, Sensitivity and Specificity of 73% each.
ROC for postoperative NT-pro-BNP against all-cause mortality:
AUC Z 77% Cut-off Z 625 pg ml1, Sensitivity 73% and Speci-
ficity 75%.
<359 82 80 77 75 74 
359 53 44 38 34 30 
Figure 4 KaplaneMeier curves showing the survival during
follow-up, according to NT-pro-BNP cut-off of 359 pg ml1.
660 S. Rajagopalan et al.a level 625 pg ml1 was an independent predictor of ACM
(odds ratio 3.9 (CI: 1.5e10) p Z 0.005).
Discussion
The current study has shown that pre- and postoperative
NT-pro-BNP levels were significantly higher in patients who
died within 2 years of major vascular surgery or who sus-
tained a MACE. The preoperative NT-pro-BNP level was an
independent predictor of both ACM and MACE. Patients<359 82 80 78 73 71 
359 53 42 36 31 29 
Figure 3 KaplaneMeier curves showing the cumulative inci-
dence of MACE during follow-up, according to NT-pro-BNP cut-
off of 359 pg ml1.with a level greater than 359 pg ml1 had an almost five
times increased risk of developing a MACE, and a greater
than three times increased mortality. Postoperative NT-
pro-BNP was found to be an independent predictor of
mortality but not MACE.
Two previous studies have assessed the relationship of
preoperative NT-pro-BNP levels to medium-term outcome.
One of these studies has shown that patients with preop-
erative NT-pro-BNP levels >319 pg ml1 had a fourfold
increased (95% CI: 1.8e8.9) for ACM and 10.9 (95% CI:
4.1e27.9) for MACE in a 6-month follow-up.11 The other
study has shown that patients with a preoperative NT-pro-
BNP levels >350 pg ml1 had a 1.9-fold increased risk (95%
CI: 1.1e3.2) for ACM in a median follow-up of 2.4 years.11,12
The latter study included patients who underwent carotid
surgery, stenting or endovascular aneurysm repair in addi-
tion to lower-extremity bypasses and open AAA repairs.
Patients undergoing carotid artery procedures were found
to be at four- to six-fold lower risk than patients who
underwent abdominal aortic or peripheral bypass surgery of
sustaining a MACE. In this study, we have not done
a subgroup analysis of AAA and CLI patients due to rela-
tively small numbers.
Only one previous study has assessed the role of post-
operative NT-pro-BNP in predicting medium-term-outcome
following major vascular surgery.13 This study by Mahla
et al. found that postoperative NT-pro-BNP was a better
predictor of adverse cardiac outcome than preoperative
levels. In this study, NT-pro-BNP levels were measured on
postoperative days 3e5, whereas in our study it was
measured on postoperative day 1. NT-pro-BNP is syn-
thesised in the ventricular myocardium in response to
ventricular wall stress, related to stress-induced myocar-
dial ischaemia and/or volume overload. Thus, the admin-
istration of increased net intravenous fluids, which
may occur during surgery or in the initial postoperative
period, may lead to increased postoperative NT-pro-BNP
levels.14e16
N-terminal pro-B-type Natriuretic Peptide 661The main limitation affecting the predictive value of NT-
pro-BNP is the variation in cut-off values within the litera-
ture. For preoperative values, the two previous studies
involving vascular patients reported similar cut-off values of
319 and350pgml1 to predictmedium-termadverse cardiac
outcome. Our previous study with the same cohort of
patients derived a cut-off 309 pg ml1 for early post-
operativemyocardial injury.7 The follow-up study has shown
that the cut-off 359 pg ml1 has a higher sensitivity and
specificity to predict ACM and MACE. There is, however,
more variation in the cut-off values for postoperative NT-
pro-BNP levels. Mahla et al. had a cut-off value of
860 pgml1, whereas in this study the valuewas 625 pgml1.
This study has also shown that postoperative troponin-I
elevation is an independent predictor of MACE and ACM at 2
years following major vascular surgery. A baseline cardiac
assessment of left ventricular function was not done
routinely in all patients, as this was a pragmatic study.
However, preoperative troponin-I levels were measured in
all individuals, which has also been shown to be an adverse
outcome predictor in vascular cohort.2,17,18 None of the
patients had a preoperative troponin elevation.
The main limitation of this study is that follow-up was
done using patient notes and the hospital intranet.
However, we would like to point out that the intranet
database is kept updated on a weekly basis. Therefore, it is
unlikely that we have missed events or patients who have
migrated out of the catchment. Deaths are notified within 2
weeks by the Registrar Office to the medical records
department. We choose to analyse ACM rather than cardiac
or vascular mortality due to the patient sample size and the
inaccuracies in reporting the cause of death due to a lack of
post-mortem examinations.
It is known that NT-pro-BNP levels vary with renal
impairment. While the renal function in the two groups was
statistically similar, it remains a confounding variable with
the NT-pro-BNP results. After eliminating five patients who
had a serum creatinine >2 mg dl1 (177 mmol l1) (n Z 5),
the results have remained the same.
In this study, the derived cut-off value and the sensi-
tivity and specificity are similar to those in previous stud-
ies,11e13 but are not robust enough to be used for the
purposes of individual risk assessment. A further limitation
is that subgroup analysis for the odds ratio for patients
undergoing AAA repair and surgery for severe limb
ischaemia is not possible due to the sample size, although
the incidence of ACM was higher in patients with limb
ischaemia than those with AAA.Conclusion
This study has shown that preoperative NT-pro-BNP is an
independent predictor and thus a useful tool in risk assess-
ment for adverse cardiac events and ACM in the medium-
term. Postoperative NT-pro-BNP is less useful and may be
influenced by factors such as postoperative fluid regimens.
Consensus does not yet exist on the optimum cut-off value
for NT-pro-BNP and further work is required in this area. This
study has shown that both NT-pro-BNP and postoperative
troponin-I elevation are independent predictors of MACE and
ACM at 2-year follow-up in the same vascular surgical cohort.Conflict of Interest
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